EGFR and lung cancer: Epalrestat restored the chemosensitivity of lung cancer cells resistant to epidermal growth factor receptor (EGFR), and tyrosine kinase inhibitor (TKI), in addition to delaying resistance in a murine lung cancer xenograft model [157].